Effects of quetiapine on cognitive functions in schizophrenia
Progress in Neuro-Psychopharmacology and Biological Psychiatry, ISSN: 0278-5846, Vol: 29, Issue: 2, Page: 233-238
2005
- 37Citations
- 64Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations37
- Citation Indexes37
- 37
- CrossRef19
- Captures64
- Readers64
- 59
Article Description
All atypical antipsychotic drugs with complex pharmacology have been shown to improve some, but not all, domains of cognitive function, including quetiapine, i.e., the agent with the most rapid dissociation from dopamine receptors and a relatively weak serotonin antagonism. The present study was to evaluate which, if any, areas of cognition improve in patients with schizophrenia, following a brief treatment with quetiapine.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0278584604002477; http://dx.doi.org/10.1016/j.pnpbp.2004.11.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=13444271974&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/15694229; https://linkinghub.elsevier.com/retrieve/pii/S0278584604002477; https://dx.doi.org/10.1016/j.pnpbp.2004.11.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know